Tag: Cobenfy Drug

Bristol Myers Q3 Beat Fails to Shift Our Stock Caution

Bristol Myers Q3 Beat Fails to Shift Our Stock Caution

Bristol Myers just posted a solid Q3 beat and hiked full-year sales guidance to $47.5B-$48B. Shares jumped 6%, but we...

30/10/2025

2 views

Trimming Bristol Myers Position After Earnings Surge

Trimming Bristol Myers Position After Earnings Surge

Shares of this major drugmaker jumped over 4% on a solid earnings beat and raised guidance. But we're selling 300...

30/10/2025

2 views

?>